Saltar al contenido
Merck

Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.

The Journal of dermatology (2002-11-16)
Kazumasa Morita, Motonobu Nakamura, Miyako Nagamachi, Tatsuo Kishi, Yoshiki Miyachi
RESUMEN

Topical immunotherapy is effective for severe alopecia areata. However, there are patients with alopecia areata refractory to topical immunotherapy alone. We tried SADBE (squaric acid dibutylester) topical immunotherapy combined with topical dry ice cryotherapy, carpronium chloride (a parasympathetic nerve stimulant) and/or oral cepharanthin (a biscoclaur alkaloid) in alopecia areata refractory to topical SADBE. Seventeen patients with alopecia areata (3 multiple, 3 ophiasis, 5 totalis and 6 universalis) were treated with SADBE in our department in 1999 to 2001. In 3 cases (2 multiple and 1 universalis) out of the 17 cases, cosmetically acceptable regrowth of hair was observed in several months with topical SADBE alone. In the other 14 cases, the SADBE therapy alone for several months (mean: 6.9 months) resulted in no or poor regrowth of hair. However, with subsequent combination therapy of topical SADBE for several months (mean: 7.6 months), satisfactory regrowth of hair was observed in 6 of the 14 cases. Our cases indicate that combination therapy of topical SADBE with other therapies can be a choice for alopecia areata which is refractory to topical SADBE therapy alone.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
3,4-Dibutoxy-3-cyclobutene-1,2-dione, 98%